Interventional Cardiology News and Research

RSS

The Transcatheter Cardiovascular Therapeutics 2009 to feature PLCs' RenalGuard System

PLC Systems Inc. (OTC Bulletin Board: PLCSF), a company focused on innovative cardiac and vascular medical device-based technologies, today announced that it will demonstrate its RenalGuard System(TM) at Transcatheter Cardiovascular Therapeutics (TCT) 2009, sponsored by the Cardiovascular Research Foundation, September 21 - 25, 2009, in San Francisco, California. More than 11,000 clinicians and professionals are expected to attend this event.

21 Sep 2009

Abbott introduces XIENCE PRIME Everolimus Eluting Coronary Stent System for global market

Abbott (NYSE: ABT) today announced at the European Society of Cardiology Congress the widespread availability of its next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.

31 Aug 2009

Initial abstract for the clinical study of PLC's RenalGuard System published

PLC Systems Inc. (OTC Bulletin Board: PLCSF), a company focused on innovative cardiac and vascular medical device-based technologies, today announced that the initial abstract for the investigator-sponsored clinical study of its RenalGuard System(TM) has been published, in advance of the annual meeting of the European Society of Cardiology, August 29 - September 2, 2009 in Barcelona, Spain, on the ESC website.

26 Aug 2009

First patient enrolled for IDEV Technologies' SUPERB clinical trial

IDEV(R) Technologies, Incorporated, (IDEV) an emerging leader in the development and marketing of minimally invasive medical technologies, today announced that the first patient was enrolled in the Company's FDA-approved multi-center clinical trial of its self-expanding SUPERA(R) stent, a novel stent platform designed for the treatment of biliary and peripheral artery disease (PAD) in the superficial femoral artery (SFA).

25 Aug 2009

TCT Featured Clinical Trials to be presented on September 24 in San Francisco

A series of Featured Clinical Trials will be presented at Transcatheter Cardiovascular Therapeutics (TCT), in addition to late-breaking clinical trials. These featured clinical trials represent groundbreaking research and will yield data and insight that will further the field of interventional cardiology.

21 Aug 2009

Studies indicate why females do not fare as well as men in undergoing angioplasty for heart attacks

Age, condition and treatment delay are among the reasons women who undergo angioplasty for heart attack often do not fare as well as do men, according to two studies presented today at the Society for Cardiovascular Angiography and Interventions (SCAI) 32nd Annual Scientific Sessions.

6 May 2009

Hybrid cardiac revascularization procedures

Patients with coronary artery disease -- blockages of the vessels that feed the heart -- can be treated in a number of ways.

6 Apr 2009

Requirement for pediatric cardiac devices highlighted by off-label procedures

Nearly two-thirds of children who undergo routine interventional cardiology procedures -- those involving a catheter to treat structural disorders of the heart -- may be receiving treatment with a device that's being used for an off-label application.

30 Mar 2009

Study offers closer look at Takotsubo cardiomyopathy

"Broken heart syndrome" is still a mystery to many in the medical community, but new data from researchers at The Miriam Hospital may shed some light on the clinical characteristics and outcomes of this relatively rare, life-threatening condition.

29 Mar 2009

Combination of very low LDL and normal systolic blood pressure attenuate coronary artery disease

New data published in the March 31, 2009, issue of the Journal of the American College of Cardiology show that patients with coronary artery disease (CAD) who achieve very low levels of low-density lipoprotein (LDL) cholesterol along with normal systolic blood pressure have the slowest progression of CAD.

23 Mar 2009

Bioabsorbable stents show promise

A study published online in The Lancet presented two year data for the bioabsorbable everolimus coronary stent.

15 Mar 2009

Back from the dead twice

“I died twice,” says a teary-eyed DeWayne Lark, “If I didn't believe in miracles before, I believe in them now.”

20 Feb 2009

Researcher develops method to combat congenital heart disease in children

Congenital heart defects account for five times more deaths annually than all childhood cancers combined.

9 Feb 2009

Timing is everything for some heart attack patients

There is strong evidence that getting to the hospital quickly during a heart attack is critical, since early treatment saves both lives and heart muscle. And if the responsible coronary artery is completely blocked, it should be opened as soon as possible.

11 Nov 2008

Fibrin-derived peptide FX06 reduces cardiac reperfusion injury

Data presented today at the European Society of Cardiology Congress demonstrates the effectiveness of a peptide called FX06 in preventing cardiac damage resulting from treatment following a heart attack.

2 Sep 2008

Drug eluting stents: New elements in the debate

Results announced at the 2006 ESC meeting in Barcelona questioned the long-term safety of drug eluting stents (DES) and sparked intense discussion.

31 Aug 2008

Who needs cardiac surgery?

Throughout the developed world, cardiac surgery faces increasing challenges from percutaneous intervention, currently with revascularisation, but potentially soon for valve replacement as well. The spectacular growth of PCI in the UK over the last five years is typical for many developed countries.

31 Aug 2008

Patients arriving at hospitals in daytime hours get faster, better care compared to off hours

Patients hospitalized with heart attacks tend to get faster and more comprehensive care if they arrive during daytime hours, according to a report in Circulation: Journal of the American Heart Association.

21 Apr 2008

Matrix registry probes adherence to clopidogrel at 1 year

A large community-based registry of patients treated with drug-eluting stents is providing important insight into how long patients with complex coronary artery disease typically stick to their doctors' orders to take clopidogrel, a drug that prevents unwanted blood clots; why they stop taking the drug; and the long-term consequences of that decision.

1 Apr 2008

First clinical trial data of a fully bioabsorbable drug-eluting stent

Data published today in The Lancet from ABSORB, the world's first clinical trial of a fully bioabsorbable drug eluting stent for the treatment of coronary artery disease, demonstrated no stent thrombosis, no clinically driven target lesion revascularizations (re-treatment of a diseased lesion), and a low (3.3 percent) rate of major adverse cardiac events (MACE) in 30 patients out to one year.

14 Mar 2008